Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25123042 | 0.84 | ALKBH2 (0.60) | HPGDSALKBH2HSD11B1 | |
| SCHEMBL25123222 | 0.81 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL7325573 | 0.79 | CA12 (0.53) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL2360322 | 0.79 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7322694 | 0.78 | MAPKAPK2 (0.48) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL8085746 | 0.78 | HPGDS (0.68) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL7320411 | 0.77 | ALDH1A1 (0.49) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL7326021 | 0.76 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL7320665 | 0.76 | ALDH1A1 (0.57) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 | |
| SCHEMBL7323051 | 0.76 | HPGDS (0.45) | NPC1RAB9ASMN1; SMN2HPGDSALKBH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |